The incidence of TP53 mutations is approximately 5–7% at diagnosis [33,34], but it rises as the disease progresses, reaching approximately 40% in refractory CLL [35,36,37,38]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.